Integra LifeSciences (IART) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
BTIG Downgrades Integra LifeSciences (IART) to Sell
July 29, 2024 4:10 PM EDTBTIG analyst Ryan Zimmerman downgraded Integra LifeSciences (NASDAQ: IART) from Neutral to Sell with a price target of $22.00.
The analyst comments "We are downgrading to SELL following 2Q24 results, setting a $22 PT at 8.5x our 12-24 month EPS estimate. Another quarter and another negative update regarding IART's manufacturing and quality controls pushing out recovery to FY26. At the same time, IART's 2Q24 results were not bad. IART reported rev. of $418.2M (9.7%, 2.3% organic, 0.3% organic ex. Boston) and adj. EPS... More
